This webinar will appeal to senior-level executives working at pharmaceutical or biotechnology companies that need a reliable pDNA supply chain.
TORONTO (PRWEB) February 13, 2020
Plasmid DNA (pDNA) plays a critical role in the delivery of gene therapies into targeted cells. The development and delivery of large quantity, high-quality pDNA vectors are in high demand.
Cytovance Biologics has developed and integrated Single-use Platform for manufacturing plasmid DNA (pDNA) using the HyperGRO™ high cell density process that is licensed from Nature Technologies, an industry leader in the field. The fermentation process reduces the risk of recombination events that are common with pDNA containing inverted repeats, such as those associated with lentiviral vectors. The fermentation is performed in single use fermenters. The platform purification employs off-the-shelf disposable technologies that ensure a low shear process.
Join featured speakers from Cytovance in a live webinar on Tuesday, March 3, 2020 at 12pm EST (5pm GMT/UK) to hear how:
- Cytovance expands its cGMP microbial services to include pDNA
- Cytovance relies on strong regulatory support and QA systems to develop a Critical Reagent Grade™ offering that is suitable as a raw material in any cGMP process
- Integrated single-use systems combine to provide high-quality pDNA
Featured speakers include:
- Jesse McCool, PhD, Chief Technology Officer
- Frank Agbogbo, PhD, Director, Microbial Bioprocess
- David Schmidt, Director, Analytical Development
This webinar will appeal to senior-level executives working at pharmaceutical or biotechnology companies that need a reliable pDNA supply chain. Specific job titles include:
- Research scientist
- Head of R&D
- Laboratory technician
- Laboratory supply chain manager
For more information or to register for this event, visit An Integrated Single-Use Platform for Manufacturing Plasmid DNA (pDNA).
About Cytovance® Biologics
Cytovance® Biologics is a leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) that excels in the rapid and cost-effective development and manufacture of large molecule active pharmaceutical ingredients (APIs) from both mammalian cell culture and microbial fermentation such as monoclonal antibodies, fragment antibodies, bispecifics, enzymes, fusion proteins, vaccines and other biological products including plasmid DNA and cell-based therapeutics. In addition to our clinical and commercial cGMP API manufacturing services, Cytovance offers well-integrated development services supporting the entire product lifecycle including cell line development, cell banking, microbial strain development, process and analytical development, and process characterization. A centralized, responsive program management team coordinates all critical chemistry, manufacturing and controls (CMC) activities for each client program around raw materials management, QC testing, ICH stability studies, and regulatory support. Our 140,000 sq. ft. state-of-the-art facilities in Oklahoma City are designed to meet U.S., EU, and other global regulatory standards.
Cytovance® offers deep industry expertise and unique customized services for the scale-up and CGMP manufacture of protein-based therapeutics; from early-stage pre-clinical development to commercial production, for both mammalian and microbial. Further information can be found at http://www.cytovance.com.